TY  - CHAP
M1  - Book, Section
TI  - Onco-Cardiology
A1  - Mouhayar, Elie
A1  - El-Haddad, Danielle
A1  - Kim, Peter
A1  - Thompson, Kara
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
PY  - 2016
T2  - The MD Anderson Manual of Medical Oncology, 3e
AB  - Onco-cardiology  is  a  fast-growing  medical  subspecialty  focused  on  the  management  of  heart  diseases  in  patients  with  cancer.  Although  cancer  remains  a  leading  cause  of  morbidity  and  mortality  worldwide,  the  survival  rate  of  patients  with  cancer  has  increased  in  the  last  25  years.  In  the  United  States,  the  5-year  relative  survival  rate  of  patients  diagnosed  with  cancer  between  1975  and  1977  was  50%;  it  increased  to  68%  between  1999  and  2005.  The  US  National  Cancer  Institute  estimates  that  at  least  13.7  million  cancer  survivors  were  alive  in  the  United  States  in  2012  (1).  With  the  survival  improvement,  the  long-term  adverse  treatment  effects  have  also  become  more  apparent.  A  survey  of  1,807  cancer  survivors  with  a  7-year  follow-up  found  that  33%  died  of  heart  diseases  and  51%  died  of  cancer  (2).  Historically,  since  the  late  1970s,  the  interest  in  chemotherapy-induced  cardiotoxicity  was  focused  on  cardiomyopathy  related  to  few  chemotherapeutic  agents.  As  the  field  of  cancer  therapies  has  expanded,  so  has  the  finding  of  other  cardiovascular  side  effects  such  as  transient  left  ventricular  dysfunction,  hypertension  (HTN),  cardiac  arrhythmias,  pericardial  effusions,  and  arterial  ischemia.  Patients  with  known  or  subclinical  cardiac  disease  are  more  susceptible  to  the  cardiotoxic  side  effects  of  cancer  therapy,  and  those  with  known  cardiac  disease  often  need  to  alter  their  cardiac  management  to  allow  for  the  treatment  of  cancer.  This  can  be  associated  with  significant  cardiovascular  risks.  Onco-cardiology  has  evolved  to  address  the  cardiovascular  needs  of  patients  whose  optimal  outcome  mandates  close  and  collaborative  efforts  between  cardiologists  and  oncologists  in  a  multidisciplinary  approach.  Involvement  of  cardiologists  in  cancer  patients’  care  has  changed  from  focusing  on  management  of  the  cardiovascular  complications  of  therapy  to  an  overall  assistance  in  the  care  of  these  patients  from  the  initial  cancer  diagnosis  to  survivorship  as  outlined  in  Fig.  54-1.  
SN  - 
PB  - McGraw-Hill Medical
CY  - New York, NY
Y2  - 2024/04/18
UR  - hemonc.mhmedical.com/content.aspx?aid=1126746530
ER  -